Osteoporosis in men: Suspect secondary disease first

Angelo Licata, MD, PhD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic

Address: Angelo Licata, MD, PhD, Department of Endocrinology, Diabetes, and Metabolism, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Merck, Lilly, Pfizer, Aventis, Wyeth Ayerst, and Novartis corporations.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.

Angelo Licata, MD, PhD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic

Address: Angelo Licata, MD, PhD, Department of Endocrinology, Diabetes, and Metabolism, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Merck, Lilly, Pfizer, Aventis, Wyeth Ayerst, and Novartis corporations.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.

Angelo Licata, MD, PhD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic

Address: Angelo Licata, MD, PhD, Department of Endocrinology, Diabetes, and Metabolism, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Merck, Lilly, Pfizer, Aventis, Wyeth Ayerst, and Novartis corporations.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.